VisionSys AI Inc is a holding company primarily engaged in the development of brain-computer interface (BCI) technologies and related businesses. The Company's main business is developing, procuring, selling, and distributing BCI-enabled or BCI-adjacent products and solutions, and to provide related technical services. The BCI technologies are used in medical and healthcare-related applications, including functional rehabilitation, communication support, neurological disease-related monitoring and intervention, sensory assistance, and general wellness management. The Company mainly operates its businesses in the domestic market.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-29	US$4.200	-0.47%	8,164
26-06-26	US$4.220	+5.24%	24,907
26-06-25	US$4.010	-4.07%	18,369
26-06-24	US$4.180	-2.34%	13,829
26-06-23	US$4.280	+0.94%	24,725

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Real-time Estimate Cboe BZX Other stock markets 14:30:53 2026-06-29 EDT			5-day change	1st Jan Change
4.205 ^USD	-0.36%		-0.94%	-82.72%

06-02	Top Premarket Gainers	MT
05-11	VisionSys AI Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	17.84M 2.62M 2.3M 2.12M 1.98M 3.73M 248M 3.81M 25.53M 9.86M 122M 9.86M 9.64M 425M	P/E 2024	-0.09x	P/E 2025	0.01x
Enterprise Value	-35.6M -5.24M -4.59M -4.23M -3.95M -7.44M -495M -7.61M -50.95M -19.67M -244M -19.67M -19.24M -848M	EV / Sales 2024	0.22x	EV / Sales 2025	-34.3x
Free-Float	13.7%	Yield 2024 *	-	Yield 2025	-

06-02	Top Premarket Gainers	MT
05-11	VisionSys AI Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-05	Visionsys Ai Inc - to change ADS ratio from 1:250 to 1:2500 effective May 26, 2026	RE
05-05	Visionsys Ai Inc - to change ADS ratio from 1:250 to 1:2500 class A ordinary shares	RE
04-28	Asian Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	MT
04-27	VisionSys AI announces proposed $90 million strategic investment at $1.50/share	RE
04-26	VisionSys AI Inc. announced that it expects to receive $90 million in funding	CI
03-27	Wall Street Set to Open Lower in Friday Trading; Investors Not Assuaged by US Deadline Extension for Iran to Open Strait of Hormuz	MT
03-13	Certain American Depositary Shares of VisionSys AI Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2026.	CI
03-13	Certain Class A Ordinary Shares of VisionSys AI Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2026.	CI
03-13	Certain Warrants of VisionSys AI Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2026.	CI
03-10	VisionSys AI Inc. announced that it expects to receive $30.21 million in funding	CI
02-12	VisionSys AI Inc. Announces Changes in Board and Committee Member	CI

25-10-24	VisionSys AI Inc Announces Board Changes	CI
23-06-14	EF Hutton Adjusts Price Target on Tarena International to $8 From $11, Keeps Buy Rating	MT
23-03-29	EF Hutton Adjusts Price Target on Tarena International to $11 From $12, Maintains Buy Rating	MT
23-02-27	EF Hutton Initiates Coverage on Tarena International With Buy Rating, $12 Price Target	MT

VisionSys AI Inc. Stock

Stocks

VSA

US8761084081

Biotechnology & Medical Research

Valuation: VisionSys AI Inc.

Chart: VisionSys AI Inc.

Latest news : VisionSys AI Inc.

Analysts' recommendations: VisionSys AI Inc.

Press Releases: VisionSys AI Inc.

Quotes and Performance

Course Extremes

Managers and Directors: VisionSys AI Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

05-20	VisionSys AI Inc Announces ADS Ratio Change with Marketplace Effective Date on May 26, 2026	GL
05-05	VisionSys AI Inc Announces Planned ADS Ratio Change	GL
05-05	VisionSys AI Inc Announces Planned ADS Ratio Change	AQ
04-27	VisionSys AI Inc. Announces Proposed $90 Million Strategic Investment at $1.50 Per Share	GL
03-27	VisionSys AI Inc. Announces Pricing of $3 Million Registered Direct Offering	GL

1 day	-0.36%
1 week	-0.94%
Current month	+8.11%
1 month	+8.11%
3 months	-38.86%
6 months	-84.78%
Current year	-82.72%

1 week	3.95	4.3
1 month	3.88	7.71
Current year	2.81	33.65
1 year	2.81	2,120.35
3 years	2.81	2,120.35
5 years	2.81	7,675
10 years	2.81	54,250

Manager	Title	Age	Since
Tian Long Wang CEO	Chief Executive Officer	40	2025-12-04
Diyu Jiang DFI	Director of Finance/CFO	-	2025-12-04
Ying Sun CEO	Chief Executive Officer	50	2021-04-07

Director	Title	Age	Since
Jian Guang Li BRD	Director/Board Member	61	2014-03-31
WU Xiaoxia BRD	Director/Board Member	-	2025-12-04
Ming Jie Sun BRD	Director/Board Member	62	2022-11-30

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VISIONSYS AI INC.	-0.36%	-0.94%	-99.17%	-99.66%	2.62M
LONZA GROUP AG	+0.94%	+7.83%	-4.50%	+3.17%	46.2B
REVOLUTION MEDICINES, INC.	+4.27%	+14.76%	+417.23%	+625.74%	38.71B
IQVIA HOLDINGS INC.	+0.47%	+14.65%	+22.08%	-13.11%	31.9B
BEONE MEDICINES AG	+3.22%	+6.32%	+19.38%	+61.82%	31.12B
CELLTRION, INC.	+8.02%	+5.23%	+17.67%	+35.36%	23.77B
ASCENDIS PHARMA A/S	+0.57%	+15.39%	-	-	16.2B
MEDPACE HOLDINGS, INC.	+0.31%	+15.63%	+67.87%	+124.26%	15.05B
EUROFINS SCIENTIFIC SE	-1.13%	+7.40%	+12.81%	+20.67%	13.74B
IONIS PHARMACEUTICALS, INC.	-0.10%	+6.56%	+104.68%	+96.72%	13.42B
Average	+1.58%	+8.76%	+62.01%	+95.00%	23.01B
Weighted average by Cap.	+2.11%	+10.07%	+94.77%	+141.02%

	2024	2025
Net sales	1.17B 172M 151M 139M 130M 245M 16.28B 250M 1.68B 647M 8.03B 647M 633M 27.89B	1.04M 153K 134K 124K 115K 217K 14.45M 222K 1.49M 574K 7.13M 574K 561K 24.75M
Net income	-587M -86.28M -75.55M -69.74M -65.13M -123M -8.16B -125M -839M -324M -4.02B -324M -317M -13.97B	1.72B 253M 221M 204M 191M 359M 23.91B 367M 2.46B 950M 11.79B 950M 929M 40.95B
Net Debt	208M 30.58M 26.78M 24.72M 23.08M 43.46M 2.89B 44.45M 297M 115M 1.43B 115M 112M 4.95B	-53.44M -7.86M -6.88M -6.35M -5.93M -11.17M -743M -11.43M -76.47M -29.52M -367M -29.52M -28.88M -1.27B